

ANNEX I

INDEX FOR CTD DOSSIER

MODULE 1: ADMINISTRATIVE AND PRESCRIBING INFORMATION

1.0 Cover letter

1.1 Comprehensive Table of Contents

1.2 Application Form

1.3 Product Information

1.3.1 SPC, Labelling and Package Leaflet

1.3.2 Mock-up

1.3.3 Specimen

1.3.4 Readability Testing

1.3.5 SPCs already approved in the Member States

1.4 Information about the Experts

1.4.1 Quality

1.4.2 Non-Clinical

1.4.3 Clinical

1.5 Specific Requirements for Different Types of Applications

1.5.1 Information for Bibliographical Applications

1.5.2 Information for Abridged Applications

1.6 Environmental Risk Assessment

1.6.1 Non-GMO

1.6.2 GMO

MODULE 2: COMMON TECHNICAL DOCUMENT SUMMARIES

2.1 CTD Table of Contents

2.2 Introduction

2.3 Quality Overall Summary – Introduction

2.3.S Quality Overall Summary – Drug Substance

2.3.P Quality Overall Summary – Drug Product

2.3.A Quality Overall Summary – Appendices

2.3.R Quality Overall Summary – Regional Information

2.4 Non-clinical Overview

2.5 Clinical Overview

2.5.1 Product Development Rationale

2.5.2 Overview of Biopharmaceutics

2.5.3 Overview of Clinical Pharmacology

2.5.4 Overview of Efficacy

2.5.5 Overview of Safety

2.5.6 Benefits and Risks Conclusions

2.5.7 Literature References

2.6 Nonclinical Written and Tabulated Summaries

2.6.1 Introduction

2.6.2 Pharmacology Written Summary

2.6.3 Pharmacology Tabulated Summary

2.6.4 Pharmacokinetics Written Summary

2.6.5 Pharmacokinetics Tabulated Summary

2.6.6 Toxicology Written Summary

2.6.7 Toxicology Tabulated Summary

2.7 Clinical Summaries

2.7.1 Summary of Biopharmaceutic and Associated Analytical Methods

2.7.2 Summary of Clinical Pharmacology Studies

2.7.3 Summary of Clinical Efficacy

2.7.4 Summary of Safety

2.7.5 References

2.7.6 Synopses of Individual Studies

MODULE 3 : QUALITY

3.2.S DRUG SUBSTANCE

3.2.S.1 General Information

3.2.S.1.1 Nomenclature

3.2.S.1.2 Structure

3.2.S.1.3 General Properties

3.2.S.2 Manufacture

3.2.S.2.1 Manufacturer(s)

3.2.S.2.2 Description of Manufacturing Process and Process Controls

3.2.S.2.3 Control of Materials

3.2.S.2.4 Controls of Critical Steps and Intermediates

3.2.S.2.5 Process Validation and/or Evaluation

3.2.S.2.6 Manufacturing Process Development

3.2.S.3 Characterization

3.2.S.3.1 Elucidation of Structure and other Characteristics

3.2.S.3.2 Impurities

3.2.S.4 Control of Drug Substance

3.2.S.4.1 Specification

3.2.S.4.2 Analytical Procedures

3.2.S.4.3 Validation of Analytical Procedures

3.2.S.4.4 Batch Analyses

3.2.S.4.5 Justification of Specification

3.2.S.5 Reference Standards or Materials

3.2.S.6 Container Closure System

3.2.S.7 Stability

3.2.S.7.1 Stability Summary and Conclusions

3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment

3.2.S.7.3 Stability Data

3.2.P DRUG PRODUCT

3.2.P.1 Description and Composition of the Drug Product

3.2.P.2 Pharmaceutical Development

3.2.P.2.1 Components of the Drug Product

3.2.P.2.1.1 Drug Substance

3.2.P.2.1.2 Excipients

3.2.P.2.2 Drug Product

3.2.P.2.2.1 Formulation Development

3.2.P.2.2.2 Overages

3.2.P.2.2.3 Physicochemical and Biological Properties

3.2.P.2.3 Manufacturing Process Development

3.2.P.2.4 Container Closure System

3.2.P.2.5 Microbiological Attributes

3.2.P.2.6 Compatibility

3.2.P.3 Manufacture

3.2.P.3.1 Manufacturer(s)

3.2.P.3.2 Batch Formula

3.2.P.3.3 Description of Manufacturing Process and Process Controls

3.2.P.3.4 Controls of Critical Steps and Intermediates

3.2.P.3.5 Process Validation and/or Evaluation

3.2.P.4 Control of Excipients

3.2.P.4.1 Specifications

3.2.P.4.2 Analytical Procedures

3.2.P.4.3 Validation of Analytical Procedures

3.2.P.4.4 Justification of Specifications

3.2.P.4.5 Excipients of Human or Animal Origin

3.2.P.4.6 Novel Excipients

3.2.P.5 Control of Drug Product

3.2.P.5.1 Specification(s)

3.2.P.5.2 Analytical Procedures

3.2.P.5.3 Validation of Analytical Procedures

3.2.P.5.4 Batch Analyses

3.2.P.5.5 Characterization of Impurities

3.2.P.5.6 Justification of Specification(S)

3.2.P.6 Reference Standards or Materials

3.2.P.7 Container Closure System

3.2.P.8 Stability

3.2.P.8.1 Stability Summary and Conclusions

3.2.P.8.2 Post-approval Stability Protocol and Stability Commitment

3.2.P.8.3 Stability Data

MODULE 4 : NONCLINICAL STUDY REPORTS

4.1 TABLE OF CONTENTS OF MODULE 4

4.2 STUDY REPORTS

4.2.1 Pharmacology

4.2.1.1 Primary Pharmacodynamics

4.2.1.2 Secondary Pharmacodynamics

4.2.1.3 Safety Pharmacology

4.2.1.4 Pharmacodynamic Drug Interactions

4.2.2 Pharmacokinetics

4.2.2.1 Analytical Methods and Validation Reports

4.2.2.2 Absorption

4.2.2.3 Distribution

4.2.2.4 Metabolism

4.2.2.5 Excretion

4.2.2.6 Pharmacokinetic Drug Interactions (nonclinical)

4.2.2.7 Other Pharmacokinetic Studies

4.2.3 Toxicology

4.2.3.1 Single-Dose Toxicity

4.2.3.2 Repeat-Dose Toxicity

4.2.3.3 Genotoxicity

4.2.3.3.1 In vitro

4.2.3.3.2 In vivo

4.2.3.4 Carcinogenicity

4.2.3.4.1 Long-term studies

4.2.3.4.2 Short- or medium-term studies

4.2.3.4.3 Other studies

4.2.3.5 Reproductive and Developmental Toxicity

4.2.3.6 Local Tolerance

4.2.3.7 Other Toxicity Studies

4.2.3.8 Other

4.3 LITERATURE REFERENCES

MODULE 5: CLINICAL STUDY REPORTS

5.1 TABLE OF CONTENTS

5.2 Tabular Listing of All Clinical Studies

5.3 Clinical Study Reports

5.3.1 Reports of Biopharmaceutic Studies

5.3.1.1 Bioavailability (BA) Study Reports

5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports

5.3.1.3 In vitro-In vivo Correlation Study Reports

5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies

5.3.2 Reports of Studies Pertinent to Pharmacokinetics using Human Biomaterials

5.3.3 Reports of Human Pharmacokinetic (PK) Studies

5.3.4 Reports of Human Pharmacodynamic (PD) Studies

5.3.5 Reports of Efficacy and Safety Studies

5.3.6 Reports of Post-Marketing Experience

5.3.7 Case Report Forms and Individual Patient Listings

5.4 Literature References

General Information

1	Company Name	Perfect Pharmaceutical Consultants Pvt. Ltd.
2	Company Address	“Prestige Classics” D-Wing, Off. No. G 4 & 5 Opp. Dr. Kanitkar’s Hospital; Dawa Bazar, Chinchwad Stn. Chinchwad; Pune-411019 Maharashtra; INDIA
3	Website	www.perfect-consultants.com
4	Years in Business	20
5	Privately owned/ Public Company	Private Ltd company
6	Number of employees	20
7	Number of employees in the field of registration procedure	15
8	Office located in	Address same as above
9	Knowledge in the chemical and pharmaceutical industry	Well versed with the current Regulatory requirements worldwide for Drug Registration.
10	Experience in the field of Active pharmaceutical ingredient API registration	Total 12 Years Experience in preparation of DMF, Registration & Answer to post submission queries, GMP Audits, etc.
11	References of successfully registered products with the drug controller	Aceclofenac, Pregabalin, Olmesartan, Docetaxel, Topotecan, Sulbactam, etc.
12	Experience in other useful fields	US-DMFs, EDMFs, CTDs, Dossiers, etc.

Contact Details

13	Main Contact	Mr. R. M. Gupta
14	Position and background of the main contact	Managing Director (M. Pharm. Tech)
15	Contact details of the main contact	E-mail:-gupta1@vsnl.com,info@perfect-consultants.com Mob. :- +91-9371020504
16	Deputy	Mr. S. Vishweshwar
17	Position and background of the deputy	Executive Director (M. Pharm.)
18	Contact details of the deputy	E-mail :- gupta2@eth.net Mob. :- +91-9370080448